HighVista Strategies Adds $3.11 Million to Tyra Biosciences Stake

HighVista Strategies disclosed the purchase of 96,218 shares in Tyra Biosciences on 15 May 2026, a transaction valued at approximately $3.11 million. According to an SEC filing, the fund increased its position in the biotechnology firm by the same number of shares compared to the previous quarter. The estimated transaction value was calculated using the quarterly average closing price.

The move raised HighVista’s stake in Tyra Biosciences to 1.39% of its 13F assets under management. The total value of the position at quarter-end rose by $4.11 million, a figure that accounts for both the new shares acquired and the appreciation in the stock price. This addition follows a period of significant market outperformance, with Tyra Biosciences shares rising 280% over the past 12 months.

As of 14 May 2026, Tyra Biosciences shares were trading at $36.51. The stock has outperformed the S&P 500 by 250 percentage points over the past year. The company, which develops targeted therapies for cancer and rare diseases, reported $383.5 million in cash, cash equivalents, and marketable securities at the end of the first quarter.

Tyra Biosciences is advancing a clinical strategy focused on FGFR3 biology, including its lead candidate TYRA-300 for muscle invasive bladder cancer. The firm recently dosed the first patient in its SURF303 study for low-grade upper tract urothelial carcinoma. Additional Phase 2 data from the company’s bladder cancer and achondroplasia programs are expected later in 2026.

The company’s preclinical-stage model relies on its proprietary SNAP platform for rapid molecular design. Management states that the current cash reserves should fund operations into the second half of 2028. While Tyra Biosciences has not yet generated product revenue, the firm is transitioning from an early-stage platform story to a catalyst-driven clinical entity.